Xiaodong D. Cheng

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications

Corrigendum to: GPX4 Inhibition Enhances the Antitumor Effect of PARP Inhibitor on Homologous Recombination Proficient Ovarian Cancer Cells.

Corrigendum to: GPX4 Inhibition Enhances the Antitumor Effect of PARP Inhibitor on Homologous Recombination Proficient Ovarian Cancer Cells.

Journal: Current cancer drug targets
Published: June 23, 2026

Erratum: Effects of lysate/tissue storage at -80°C on subsequently extracted EVs of epithelial ovarian cancer tissue origins.

Erratum: Effects of lysate/tissue storage at -80°C on subsequently extracted EVs of epithelial ovarian cancer tissue origins.

Journal: iScience
Published: February 13, 2026

Diagnostic value of FAM19A4/SOX1/PAX1 methylation in non-16/18 high-risk HPV cervical lesions.

Diagnostic value of FAM19A4/SOX1/PAX1 methylation in non-16/18 high-risk HPV cervical lesions.

Journal: Gynecologic oncology
Published: February 06, 2026

Niraparib treatment patterns and outcomes in first-line maintenance therapy for ovarian cancer: The RENI-1 study.

Niraparib treatment patterns and outcomes in first-line maintenance therapy for ovarian cancer: The RENI-1 study.

Journal: Chinese medical journal
Published: December 23, 2025

Astragalus Polysaccharides Induce Immunogenic Cell Death in Melanoma: A Mechanism Mediated by cGAS/STING Activation via Intratumoral Microbiota Modulation.

Astragalus Polysaccharides Induce Immunogenic Cell Death in Melanoma: A Mechanism Mediated by cGAS/STING Activation via Intratumoral Microbiota Modulation.

Journal: Cancer medicine
Published: October 27, 2025

The distribution of colposcopy directed ectocervical biopsy and endocervical curettage results: a retrospective study of 47,134 cases.

The distribution of colposcopy directed ectocervical biopsy and endocervical curettage results: a retrospective study of 47,134 cases.

Journal: Annals of medicine
Published: October 16, 2025

Association between tumor laterality and prognosis across different ovarian cancer subtypes: Results from SEER database and a Chinese multicenter cohort.

Association between tumor laterality and prognosis across different ovarian cancer subtypes: Results from SEER database and a Chinese multicenter cohort.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: September 15, 2025

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Journal: CA: a cancer journal for clinicians
Published: September 15, 2025

Analysis of follow-up outcomes in patients with cervical histologic low-grade squamous intraepithelial lesion preceded by serious cytology and repeated diagnosis for at least 2 years.

Analysis of follow-up outcomes in patients with cervical histologic low-grade squamous intraepithelial lesion preceded by serious cytology and repeated diagnosis for at least 2 years.

Journal: Women's health (London, England)
Published: September 11, 2025

The Expression and Clinical Significance of C1orf106 in Low-Grade Serous Ovarian Cancer.

The Expression and Clinical Significance of C1orf106 in Low-Grade Serous Ovarian Cancer.

Journal: The journal of obstetrics and gynaecology research
Published: August 08, 2025

A Nomogram for Predicting Cancer-Specific Survival in Patients With Stage I Vulvar Squamous Cell Carcinoma: A Study Based on the SEER Database and External Validation.

A Nomogram for Predicting Cancer-Specific Survival in Patients With Stage I Vulvar Squamous Cell Carcinoma: A Study Based on the SEER Database and External Validation.

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: July 02, 2025

PCO25-211: HIF-1α Inhibitor ACF Synergizes With PARP Inhibitors Through the Exacerbation of Transcription-Replication Conflicts in Ovarian Cancer.

PCO25-211: HIF-1α Inhibitor ACF Synergizes With PARP Inhibitors Through the Exacerbation of Transcription-Replication Conflicts in Ovarian Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2025
Showing 1-12 of 134

Last Updated: 09/26/2026